MEDICAL DEVICE REGULATIONS EVOLVE FOR AUSTRALIAN INNOVATORS WITH EUROPEAN AMBITIONS Notified body and approved body attend Regulatory Summit to support access to the EU market.
With
Gabrielle Cesvet,
Head of Public Affairs, Scarlet
Tirion Evans, Head of Technical Operations &
Head of Notified Body, Scarlet
SEGMENT
Filmed in Sydney | October 2026
Medical device regulation is undergoing significant change as regulators across major jurisdictions grapple with the rapid growth of software and artificial intelligence (AI) in healthcare.
Speaking with Australian Health Journal at the Medical Technology Association of Australia’s RegConnect Summit 2026 in Sydney in September, Gabrielle Cesvet, Head of Public Affairs at Scarlet, said manufacturers need greater clarity and sufficient lead time as new regulatory frameworks emerge.
“We need to make sure that from a regulatory perspective and from a conformity assessment perspective, we’re able to keep pace with that innovation,” she said.
Cesvet highlighted reforms underway in the European Union, including efforts to simplify the Medical Device Regulation (MDR), reduce regulatory burdens and create a framework better suited to software and AI. She also pointed to the UK’s plans to revamp its regulatory system and increase international reliance.
Tirion Evans, Head of Technical Operations and Head of Notified Body at Scarlet, said the company is increasingly working with Australian manufacturers seeking access to international markets. Scarlet operates as a Notified Body in the EU, an Approved Body in the UK and a Third Party Review Organization in the US.
Evans encouraged innovators to address regulatory requirements early rather than waiting until products are fully developed.
“The most important thing is to try and tackle the regulatory issues right at the beginning,” she said.
The interviews highlighted the growing importance of regulatory expertise in helping innovative software and AI medical devices reach markets efficiently while keeping pace with technological change.
- Source: Adapted from transcript using AI
- Media access credit: Medical Technology Association of Australia (MTAA), RegConnect Summit 2026, Sydney September, 2026
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Lasers in dental treatment without needles and drills
In 2017, Dr. Omar Zuaiter and Alaa Habeb launched Dentroid, a dental technology startup with a mission to make dentistry a kinder and friendlier experience for patients and dentists using photonics (using laser technology) and robotics, as alternatives to needles, drills and sprays. The vision for the startup is to have dentistry adopt laser technology, addressing the root causes of dental pain & anxiety, and create a pain-free dental experience.
-
From refugee to receiving multiple accolades as a community pharmacist
Sara is an experienced pharmacist, community health advocate, and the Lead Pharmacist at Pharmacy 777 Pascoe Vale in Victoria. With over 20 years in the profession, Sara has played a significant role in advancing local healthcare delivery through clinical leadership, service development, and strong community partnerships.
